UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2023

Commission File Number: 001-37384

GALAPAGOS NV

(Translation of registrant's name into English)

Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F 🖂 Form 40-F 🗆

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Corporate Presentation

On January 9, 2023, Paul Stoffels (acting via Stoffels IMC BV), Chief Executive Officer of the Registrant, presented at the 41st annual J.P. Morgan Healthcare Conference in San Francisco, which took place from January 9-12, 2023. The Registrant prepared the corporate presentation for use during meetings throughout the J.P. Morgan Healthcare Conference. A copy of the corporate presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit	Description
99.1	Corporate Presentation, titled J.P. Morgan Healthcare Conference, dated January 9, 2023

The information contained in slides numbered 6, 8, 9 and 18 featured in *Exhibit 99.1* of this Report on Form 6-K, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333-218160, 333-225263, 333-231765, 333-249416, 333-260500 and 333-268756).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GALAPAGOS NV

(Registrant)

/s/ Annelies Denecker

Annelies Denecker Company Secretary

Date: January 19, 2023

J.P. Morgan Healthcare Conference

January 9, 2023




State Disclaimer

This presentation contains "forward-looking statements", all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "expect," "upcoming," "future," "estimate," "will, "would," "potential," "next, "continue," "encouraging," "Initial," "aim," "feasible," "promising," "targeting," "believe," "planned," "on track, "explore," towards," "adapt," "to deliver," "further" as well as similar expressions. Forward-looking statements contained in this presentation include, but are not limited to, statements regarding pur strategic and capital allocation priorities, statements regarding the collaboration with locas, statements regarding the analyse related to tom the ATALANTA-1 study and any other analyses related to CD19 CAR-T. and our plans and strategy with respect to the ATALANTA-1 study and any other analyses related to CD19 CAR-T. and our plans and strategy, with respect to the ATALANTA-1 study and any other analyses related to CD19 CAR-T. and our plans and strategy, with respect to the ATALANTA-1 study and any other analyses related to CD19 CAR-T. and our plans and strategy, with respect to the ATALANTA-1 study and any other analyses related to CD19 CAR-T. and our plans and strategy, statements regarding our plenien and complementary technology platform, and any potential future miles in such strategy, statements regarding the strategic re-evaluation, including the oncology vision 2028 readmap and the vision 2028 portfolio objectives, statements regarding the sepected toming, design and readouts of onpoing and in rMHL, (vi) with CD19 CAR-T. Stol1 in rKEL, (vi) with CD19 CAR-T stol1 in rKEL, (vii) with CD19 CAR

Except for fligotinib's approval as Jyseleca® for the treatment of RA and UC by the European Commission, Great Britain's Medicines and Healthcare Products Regulatory Agency, and the Japanese Ministry of Health, Labour and Welfare, our drug candidates are investigational; their efficacy and safety have not been fully evaluated by any regulatory authority.

Under no circumstances may any copy of this presentation, if obtained, by retained, copied or transmitted.

2



>>>> Towards a financially sustainable biopharma

Rebuild and accelerate R&D to bring more transformational medicines to patients within 5 years >€4Bn cash &

disciplined cash use to deliver innovation output that contributes to value creation

Based on Galapagos management estimates

4

Leverage our strong fundamentals

5




>>>> Portfolio focus on immunology & oncology

Class	Asset		Phase 1	Phase 2	Phase 3	Approval
JAK1	filgotinib			AxSpA	CD	RA & UC
TYK2 SIKi CD19 CAR-T	`3667 PCC `5101	rSLE	SLE	DM		
CD19 CAR-T	`5101		NHL	,		
CD19 CAR-T	`5201		CLL			
BCMA		MM				
Next-gen CA	R-T			-	Immunology Oncology	/
Aim to start Ph1b with CD19 CAR-T in SLE						

Note: fligotinib is approved for RA and UC in EU, Great Britain and Japan; '2737 Phase 2 program in polycystic kidney disease ongoing with topline results expected in the first half of 2023. If successful, we aim to outlicense the progra AcSpA, axial spondyloarthritis; CD, Crohn's disease; RA, rheumatoid arthritis; UC, ulcerative colitis; rSLE, refractory systemic lupus erythematosus; DM, dermatomyositis; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; MM, mu myeloma 6 Galápago


Jyseleca European net sales guidance 2022 of €80-€90M



Ph3 CD topline 1H23; Aim to start Ph3 for AxSpA in 2023

*Guidance on European net sales based on Galapagos management projections. Original guidance for FY22 was E65-75M; updated at H1 update to E75-85M and updated at Q3 to E80-90M

Adding CD19 CAR-T to our immunology portfolic



Galapago

Targeting refractory SLE with CD19 CAR-T

Potential to reset immune system of SLE patients

- Severe rSLE
 - > SLE patients with (multiple) organ threatening disease
 - high unmet medical need
 - 2-3% of total SLE population worldwide*
- Breakthrough academic results reported in 5/5 rSLE patients treated with CD19 CAR-T**
 - elimination of pathogenic B-cells
 - > durable, drug-free remission, repopulation of healthy B-cells
 - > encouraging safety profile
- Potential in broad range of autoimmune diseases

Aim to start a Ph1b with '5101 in severe rSLE in 2023

*Total SLE population: 1.4 million diagnosed wondwide (Evaluate Epi / ImmuPharma). Kim et el "Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials." Lupus Sci Med 2018 **Mackensen et al "Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus." Nature Medicine 2022

9

>>> `3667 shows promise as selective TYK2i



Start Ph2s with '3667 in dermatomyositis and SLE in 2023

Pso: psoriasis

10

Solution Soluti Solution Solution Solution Solution Solution Solution Solut

Towards 3 next-generation cell therapies in 3 years

2023-25

Medium term

Build a pipeline of Best-in-Class cell therapies Global scalable CAR-T platform

2025 - 2028 +

Longer term

Leverage capabilities to rapidly address unmet needs in oncology

2022-23

Short term

Validate the **decentralized CAR-T** delivery model with proven therapies

BCMA, B-cell maturation antigen; ADC, antibody drug conjugate

11

Addressing an unmet medical need with point-of care CAR-T therapy

Access	 Manufacturing constraints & logistics hamper efficient treatment by physicia Centralized production results in high drop-out rates & mortality
Durability	High relapse rateImmunogenicity prevents redosing
Toxicity	High occurence of toxicity leads to intensive care hospitalization
Decentraliz	zed model has potential to address patients' need for global access to CAR-T

CAR-T: Chimeric Antigen Receptor T-cell Source: ClarivateTH Research, 2022

12


Solution Cocoon[®]: fully-closed sterile system for CAR-T



© Lonza, reproduced with permission


13

Increase patient access with point-of-care delivery



ATALANTA CD19 CAR-T Ph1/2a in r/rNHL


Evaluating feasibility, safety and efficacy of point-of-care CD19 CAR-T



DL, dose level; r/rtlHL, refractory/relapsed non-Hodgkin lymphoma. Start of dose expansion in 2023 pending regulatory approva

15

Encouraging first patient data with `5101



ORR, objective response rate; CR, complete response; DL1, dose level 1; DL2, dose level 2 Limit of quantification (LOQ) is 1000 vector copies. Presented at ASH 2022: December 12, 2022 © ASH 16

Section No CRS and ICANS Grade ≥3 at DL1 and DL2

	All doses N=8	DL1 (50x10 ⁶ cells) N=4	DL2 (110x10 ⁶ cells) N=4
Patients with any grade CRS, n (%)	4 (50)	0	4 (100)
Grade 1/2	4	0	4
Grade ≥3	0	0	0
Median time to onset, median duration (days)	7, 3	0	7, 3
Neurotoxicity (ICANS), n (%)	3 (38)	0	3 (75)
Grade 1	3	0	3
Grade ≥3	0	0	0
Median time to onset, median duration (days)	8, 2	0	8, 2
Toxicity management, n (%)			
Tocilizumab	3 (38)	0	3 (75)
Dexamethasone	1 (13)	0	1 (25)

Initial data '5101 show encouraging safety profile in r/rNHL

DL, dose level; CRS, cytokine release syndrome; ICANS, Im Presented at ASH 2022: December 12, 2022 © ASH 17

Solutiook 2023

Topline results

- Filgotinib DIVERSITY Ph3 CD
- CD19 CAR-T Ph1b NHL
- CD19 CAR-T Ph1b CLL
- `2737 MANGROVE Ph2 ADPKD

Regulatory progress

CD19 & BCMA CAR-T IND submission

Trial initiations


- Filgotinib Ph3 AxSpA
- CD19 CAR-T Ph1b rSLE
- CD19 CAR-T NHL/CLL expansion cohorts
- BCMA CAR-T Ph1b MM
- '3667 (TYK2i) Ph2 DM & SLE

Aim to execute on additional business development deals

ADPKD, Autosomal dominant polycystic kidney disease; BCMA, B cell maturation antigen

18

Vision 2028 portfolio objectives



SME, small molecular entity; TA, therapeutic area

19



